drugset / Trial / NCT07215260

A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body

NCT07215260

Phase 1 Completed 14 enrolled Boehringer Ingelheim
NaCrossoverOpen-labelTreatment

Summary

The objective of this trial is to assess the effect of BI 3000202 on the pharmacokinetics of rosuvastatin and digoxin given as a cocktail.

Timeline

Start
2025-11-05
Primary completion
2025-12-07
Completion
2025-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3000202 Unknown
Subject Digoxin Other / unclassified
Subject Rosuvastatin Small molecule

Indications

No indication recorded.